FreeMind Group to assist biOasis (BTI:TSXV)Please contact me with any questions.
Graeme
M: 1-403-561-8989
E: graeme@colwellcapital.com; or info@bioasis.ca
________________________________________ June 15, 2017, Vancouver, BC
BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI) announced today it has engaged FreeMind Group to assist the Company pursue non-dilutive funding opportunities globally.
The biOasis Transcend technology has been demonstrated to transport several different drug modalities (e.g., antibodies, enzymes, small molecules) across the blood-brain barrier (BBB) and into the central nervous system (CNS). The value in Transcend is the potential to turn non-brain-penetrant drugs into novel medical entities, to deliver them to the brain and to treat a range of disorders (e.g., oncology, lysosomal disorders and neurodegenerative diseases). Therefore, Transcend has the potential to treat more than one hundred identified brain and other CNS disorders.
Non-dilutive funding is available for many of these disorders from multiple government and private sources. FreeMind Group has the expertise to identify these funding sources and to assist biOasis throughout the funding process, from the preparation and submission of funding applications to pre-award negotiations.
“As we advance our internal programs, it is important to continue to drive new scientific discoveries and understand which diseases the Transcend platform may best serve. To this end, Freemind is an important strategic addition to our armamentarium. Dr. Reinhard Gabathuler, chief scientist, biOasis, will manage this collaboration,” said Dr. Mark Day, chief executive officer.
“FreeMind can play an important dual role for us, both protecting shareholder value and helping biOasis identify potential diseases and translational endpoints of interest,” said Dr. Day. “Much of the work we will conduct fits well within the mandate of many organizations that provide this type of non-dilutive funding. FreeMind has a strong track record and is highly regarded by academia, industry, and the funding organizations. This should provide biOasis with greater opportunities for success in the grant funding process.”
About FreeMind
Established in 1999, FreeMind is the largest consulting group of its kind working with academics and industry alike. FreeMind assists in maximizing potential to receive funding from non-dilutive sources such as the NIH, DOD, NSF, FDA, BARDA, as well as private foundations. FreeMind assists in the guiding of non-dilutive funding efforts from identification of the most suitable opportunity through to submission and subsequent award. FreeMind has garnered its clients over $1.5 billion to date. Awards range from $150,000 to $150million per project.
About Transcend
Transcend is biOasis’ proprietary platform for the delivery of therapeutics across the blood-brain barrier to address unmet medical needs in the treatment of metastatic brain cancers as well as neurodegenerative and metabolic diseases. The delivery of therapeutics across the blood-brain barrier represents the single greatest challenge in treating neurological disorders. The ability to effectively and safely transverse the blood-brain barrier with the Transcend peptide carrier, MTfp, offers the opportunity for biOasis to deliver therapeutics into the brain at doses sufficient to have a therapeutic effect.
About biOasis
biOasis Technologies Inc. is a biopharmaceutical company headquartered in the Vancouver, Canada area, focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB). The company is developing and commercializing a proprietary brain delivery technology to address unmet medical needs in the treatment of central nervous system disorders. biOasis trades on the OTCQB under the symbol “BIOAF” and on the TSX Venture Exchange under the symbol “BTI.” For more information about the company please visit www.bioasis.ca.